ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette–Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC).
Saved in:
| Title: | ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette–Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC). |
|---|---|
| Authors: | Roupret, M.1 (AUTHOR) morgan.roupret@aphp.fr, Bertaut, A.2 (AUTHOR), Pignot, G.3 (AUTHOR), Neuzillet, Y.4 (AUTHOR), Houede, N.5 (AUTHOR), Mathieu, R.6 (AUTHOR), Corbel, L.7 (AUTHOR), Besson, D.8 (AUTHOR), Seisen, T.1 (AUTHOR), Jaffrelot, L.9 (AUTHOR), Lebacle, C.10 (AUTHOR), Champiat, S.11 (AUTHOR), Lebdai, S.12 (AUTHOR), Timsit, M.-O.13 (AUTHOR), Thibault, C.14 (AUTHOR), Goeman, L.15 (AUTHOR), Juárez Soto, Á.16 (AUTHOR), La, C.17 (AUTHOR), Léger, C.17 (AUTHOR), Loriot, Y.1,18 (AUTHOR) yohann.loriot@gustaveroussy.fr |
| Source: | Annals of Oncology. Jan2026, Vol. 37 Issue 1, p44-52. 9p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2025.09.017 |
